Biomarkers and clinical scoring systems in community-acquired pneumonia
Community-acquired pneumonia (CAP) is the third most common cause of death globally. Due to the complexity of CAP, it is widely accepted that, currently, clinical prognosis and diagnosis is inadequate for the assessment of the severity of the disease. With the aim to determining the initial treatmen...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2019-01-01
|
Series: | Annals of Thoracic Medicine |
Subjects: | |
Online Access: | http://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2019;volume=14;issue=3;spage=165;epage=172;aulast=Karakioulaki |
id |
doaj-419eb2e10a714fbca89d71020023b96b |
---|---|
record_format |
Article |
spelling |
doaj-419eb2e10a714fbca89d71020023b96b2020-11-24T21:26:39ZengWolters Kluwer Medknow PublicationsAnnals of Thoracic Medicine1817-17371998-35572019-01-0114316517210.4103/atm.ATM_305_18Biomarkers and clinical scoring systems in community-acquired pneumoniaMeropi KarakioulakiDaiana StolzCommunity-acquired pneumonia (CAP) is the third most common cause of death globally. Due to the complexity of CAP, it is widely accepted that, currently, clinical prognosis and diagnosis is inadequate for the assessment of the severity of the disease. With the aim to determining the initial treatment and the appropriate level of intervention, several clinical scores of severity and biomarkers have been developed. Both biomarkers and clinical scoring systems are expected to determine the different aspects of the host factor and the response to therapy, in order for physicians to be able to make an accurate benefit/risk assessment that will lead to proper diagnosis and correct prescription of antibiotics. This review aims to highlight the prognostic and diagnostic accuracy of various laboratory and clinical parameters in CAP and discuss the perspectives for the reduction of CAP mortality.http://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2019;volume=14;issue=3;spage=165;epage=172;aulast=KarakioulakiBiomarkerscommunity-acquired pneumoniaclinical scoring systems |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Meropi Karakioulaki Daiana Stolz |
spellingShingle |
Meropi Karakioulaki Daiana Stolz Biomarkers and clinical scoring systems in community-acquired pneumonia Annals of Thoracic Medicine Biomarkers community-acquired pneumonia clinical scoring systems |
author_facet |
Meropi Karakioulaki Daiana Stolz |
author_sort |
Meropi Karakioulaki |
title |
Biomarkers and clinical scoring systems in community-acquired pneumonia |
title_short |
Biomarkers and clinical scoring systems in community-acquired pneumonia |
title_full |
Biomarkers and clinical scoring systems in community-acquired pneumonia |
title_fullStr |
Biomarkers and clinical scoring systems in community-acquired pneumonia |
title_full_unstemmed |
Biomarkers and clinical scoring systems in community-acquired pneumonia |
title_sort |
biomarkers and clinical scoring systems in community-acquired pneumonia |
publisher |
Wolters Kluwer Medknow Publications |
series |
Annals of Thoracic Medicine |
issn |
1817-1737 1998-3557 |
publishDate |
2019-01-01 |
description |
Community-acquired pneumonia (CAP) is the third most common cause of death globally. Due to the complexity of CAP, it is widely accepted that, currently, clinical prognosis and diagnosis is inadequate for the assessment of the severity of the disease. With the aim to determining the initial treatment and the appropriate level of intervention, several clinical scores of severity and biomarkers have been developed. Both biomarkers and clinical scoring systems are expected to determine the different aspects of the host factor and the response to therapy, in order for physicians to be able to make an accurate benefit/risk assessment that will lead to proper diagnosis and correct prescription of antibiotics. This review aims to highlight the prognostic and diagnostic accuracy of various laboratory and clinical parameters in CAP and discuss the perspectives for the reduction of CAP mortality. |
topic |
Biomarkers community-acquired pneumonia clinical scoring systems |
url |
http://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2019;volume=14;issue=3;spage=165;epage=172;aulast=Karakioulaki |
work_keys_str_mv |
AT meropikarakioulaki biomarkersandclinicalscoringsystemsincommunityacquiredpneumonia AT daianastolz biomarkersandclinicalscoringsystemsincommunityacquiredpneumonia |
_version_ |
1725978247225671680 |